Food and Drug Administration (FDA) approved Rybelsus, the oral version of Semaglutide from Novo Nordisk, for reducing the risk of major cardiovascular events in adults with Type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk, including those without prior heart attack or stroke
Some patients find that certain foods increase nausea or stomach discomfort during the early stages of treatment
doi:10.1016/S0140-6736(19)31149-3 29
Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E (2006)
The initial mealtime dose of RAI should be 4 U, 0.1 U/kg BW, or 10% of the basal dose (possibly with a reduction in basal insulin dose by the same amount in patients with a HbA1c level of 140 mg/dL) [3]